Drug intelligence / Profile preview

SESC-01

Development stage: Phase 2
Lead developer: South End Skin Care
Modality: Small Molecules
Administration: Topical

Overview

SESC-01 is an experimental drug developed by South End Skin Care. It is being investigated primarily for the treatment of infectious diseases, with a particular focus on skin and fungal infections such as tinea pedis (athlete's foot). The highest reported R&D status for SESC-01 is "Pending," indicating it has not yet reached advanced clinical development or approval stages. Detailed information about its mechanism of action, molecular structure, or pharmacological class has not been disclosed in public sources[1][2][7].

Beyond the preview

Go deeper on SESC-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SESC-01.

Explore the full profile